PPLPHARMA

What Piramal Pharma promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 19 tracked 2 delivered 3 missed 14 open
  • Consolidated Revenue Growth missed said Q4 FY25 Promised: mid-single-digit consolidated revenue for FY26 Q1 FY27: This promise for a past fiscal year was not mentioned.
  • Consolidated Revenue Growth revised up said Q4 FY25 Promised: mid- to high-teen revenue growth in FY27 Q1 FY27: Management upgraded FY27 guidance back to 'mid-to-high teen revenue growth', from the 'early-to-mid-teen' guidance given in Q4 FY26. Q1 FY27 performance of 17% YoY growth supports this.
  • Total Revenue on track said Q2 FY25 Promised: $2 billion revenue by FY30 Q1 FY27: The FY30 revenue target was not explicitly mentioned, but the corresponding FY30 EBITDA margin target was reiterated, suggesting the long-term plan remains intact.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 19 tracked commitments for Piramal Pharma — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens